CLNN

Clene Inc

3.86

Oct 09 • 3:59 PM ET -0.02 (-0.52%)

3.83

Aftermarket • 7:30 PM ET -0.03 (-0.72%)

Healthcare Biotechnology USA Micro NASD

Peers: ANIX ATYR COYA CYPH INO LONA NRXS CGTX NRXP KALA

| Held by: VTI VXF IWC

Scroll to Statements

Index	-
Market Cap	54.87M
Enterprise Value	67.54M
Income	-39.52M
Sales	0.20M
Book/sh	-1.94
Cash/sh	0.68
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	79
IPO	Aug 27, 2018

P/E	-
Forward P/E	-
PEG	-
P/S	274.33
P/B	-
P/C	5.67
P/FCF	-
EV/EBITDA	-
EV/Sales	337.68
Quick Ratio	3.07
Current Ratio	3.07
Debt/Eq	-
LT Debt/Eq	-
Option/Short	Yes / Yes

EPS (ttm)	-3.51
EPS next Y	-1.50
EPS next Q	-0.45
EPS this Y	2.87%
EPS next Y	41.88%
EPS next 5Y	-
EPS past 3/5Y	33.86% 34.50%
Sales past 3/5Y	-24.94% -0.59%
EPS Y/Y TTM	-35.10%
Sales Y/Y TTM	-31.12%
EPS Q/Q	-39.17%
Sales Q/Q	233.33%
Earnings	Aug 14 BMO
EPS/Sales Surpr.	-193.48% 47.54%

Insider Own	22.56%
Insider Trans	-8.52%
Inst Own	22.64%
Inst Trans	2.49%
ROA	-174.99%
ROE	-
ROIC	-
Gross Margin	-657.36%
Oper. Margin	-10431.98%
Profit Margin	-20059.90%
SMA20	-4.88%
SMA50	-9.36%
SMA200	-27.85%
Trades

Shs Outstand	12.78M
Shs Float	11.01M
Short Float	8.00%
Short Ratio	8.85
Short Interest	0.88M
52W High	13.50 -71.41%
52W Low	3.25 18.77%
Volatility	6.33% 8.86%
ATR (14)	0.31
RSI (14)	42.33
Beta	1.04
Rel Volume	0.48
Avg Volume	99.50K
Volume	48,131

Perf Week	-5.39%
Perf Month	5.75%
Perf Quarter	-39.59%
Perf Half Y	-36.82%
Perf YTD	-34.24%
Perf Year	-59.11%
Perf 3Y	-63.45%
Perf 5Y	-97.19%
Perf 10Y	-
Recom	1.00
Target Price	32.20
Prev Close	3.88
Price	3.86
Change %	-0.52%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-04-22	Downgrade	Oppenheimer	Outperform → Perform
Jul-18-22	Initiated	H.C. Wainwright	Buy	$16
May-02-22	Initiated	Canaccord Genuity	Buy	$10
Sep-28-21	Initiated	Oppenheimer	Outperform	$20

Sep-22-26 08:00AM	Clene to Present at Upcoming Investor Conferences (GlobeNewswire)
Sep-21-26 08:30AM	Clene Announces Closing of $4 Million Registered Direct Offering Extending Capital Runway Beyond FDA Decision on CNM-Au8 NDA (GlobeNewswire)
Sep-15-26 09:00AM	Clene Announces $4 Million Registered Direct Offering (GlobeNewswire) +22.56%
Sep-03-26 08:00AM	Clene to Present at Upcoming September Investor Conferences (GlobeNewswire)
Aug-31-26 10:34AM	NeuroSense Rewrites the Standard ALS Playbook With a Faster, Leaner Path to Potential Approval (FinanceWire)
08:30AM	Loading…
Aug-17-26 08:30AM	Clene to Present at the Emerging Growth Conference (GlobeNewswire)
Aug-14-26 08:30AM	Clene Reports Second Quarter 2026 Financial Results and Recent Operating Highlights (GlobeNewswire)
Aug-10-26 08:00AM	Clene Announces Biomarker Analyses To Be Included in NDA Submission Supporting ALS Accelerated Approval (GlobeNewswire)
Jul-29-26 08:30AM	Clene to Present at The Canaccord 46th Annual Growth Conference (GlobeNewswire) -5.41%
May-14-26 08:00AM	Clene Reports First Quarter 2026 Financial Results and Recent Operating Highlights (GlobeNewswire) +8.46%
May-05-26 08:45AM	Clene Announces $7 Million Underwritten Offering of Common Stock (GlobeNewswire) -18.67%
08:00AM	Clene to Present at Upcoming May Conferences (GlobeNewswire)
May-04-26 08:00AM	After Successful FDA Meeting, Clene Filing Accelerated Approval NDA for ALS (GlobeNewswire) +31.76%
Mar-12-26 08:00AM	Clene Reports Full Year 2025 Financial Results and Recent Operating Highlights (GlobeNewswire) +6.09%
Feb-26-26 12:07AM	Clene Touts FDA Path for ALS Drug CNM-Au8, Highlights Biomarkers, Extends Cash Runway (MarketBeat) +8.06%
08:00AM	Loading…
Feb-24-26 08:00AM	Clene Issues Stockholder Letter Highlighting Upcoming CNM-Au8 2026 Catalysts (GlobeNewswire) +9.80%
Feb-19-26 08:30AM	Clene to Present at the Emerging Growth Conference (GlobeNewswire)
Jan-23-26 01:02AM	Clene Conference: FDA Grants Type C Meeting as CLNN Eyes ALS CNM-Au8 Accelerated Approval in Q2 (MarketBeat)
Jan-16-26 08:30AM	Clene to Present at the Emerging Growth Conference (GlobeNewswire)
Jan-12-26 08:30AM	Clene Announces Additional CNM-Au8 Biomarker Data Supporting Potential NDA Filing for Upcoming In-Person FDA Meeting (GlobeNewswire) -19.00%
Jan-09-26 08:30AM	Clene Announces Registered Direct Offering of Over $28 Million (GlobeNewswire) +7.12%
Dec-09-25 08:30AM	Clene to Present at the Emerging Growth Conference (GlobeNewswire) +6.31%
Dec-03-25 08:00AM	Clene Announces Statistically Significant ALS Biomarker Results Supporting Accelerated Approval Pathway for CNM-Au8 (GlobeNewswire) -22.03%
Dec-02-25 05:39PM	Clene to Provide CNM-Au8 ALS Program Update (GlobeNewswire)
Nov-20-25 08:00AM	Clene to Participate at the Benchmark 14th Annual Discovery One-on-One Investor Conference (GlobeNewswire)
Nov-13-25 09:00AM	Clene Inc. (CLNN) Reports Q3 Loss, Lags Revenue Estimates (Zacks) -22.42%
08:00AM	Clene Reports Third Quarter 2025 Financial Results and Recent Operating Highlights (GlobeNewswire)
Nov-10-25 05:15PM	Oculis Holding AG (OCS) Reports Q3 Loss, Beats Revenue Estimates (Zacks) -5.35%
Nov-06-25 08:25AM	C4 Therapeutics, Inc. (CCCC) Reports Q3 Loss, Beats Revenue Estimates (Zacks) -14.19%
Oct-20-25 08:30AM	Clene to Present at the Emerging Growth Conference (GlobeNewswire)
08:30AM	Loading…
Oct-15-25 08:30AM	Clene to Participate in a Panel Discussion at the Maxim Growth Summit (GlobeNewswire)
Sep-25-25 08:00AM	Clene Presents New Clinical Data at ECTRIMS 2025 Meeting Demonstrating CNM-Au8 Improves Brain Energy Metabolism in Multiple Sclerosis Patients (GlobeNewswire)
Sep-04-25 08:30AM	Clene Presents Preclinical Data Supporting CNM-Au8 for the Treatment of Parkinson's Disease (GlobeNewswire) +6.44%
Sep-02-25 08:00AM	Clene to Present at the H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire) +20.11%
Aug-14-25 09:15AM	Clene Inc. (CLNN) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
09:10AM	MeiraGTx Holdings PLC (MGTX) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
08:38AM	Clene Reports Second Quarter 2025 Financial Results and Recent Operating Highlights (GlobeNewswire)
Aug-13-25 08:00AM	Clene to Present at the Emerging Growth Conference (GlobeNewswire)
Aug-12-25 05:20PM	Absci Corporation (ABSI) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
Aug-05-25 08:30AM	Clene to Present at the Canaccord 45th Annual Growth Conference (GlobeNewswire)
Aug-04-25 05:20PM	Castle Biosciences, Inc. (CSTL) Q2 Earnings and Revenues Surpass Estimates (Zacks) +7.16%
Jul-16-25 07:00AM	Presenting on Emerging Growth Conference 84 Day 2 on July 17; Register to live stream (GlobeNewswire)
Jun-30-25 08:00AM	Clene Provides Regulatory Update Following Constructive FDA Type-C Meeting on Neurofilament Biomarker Analysis Plan and Confirms Two Additional FDA Meetings (GlobeNewswire)
Jun-09-25 09:00AM	Clene Inc. Chief Executive Officer Rob Etherington to Present at the Investor Summit Virtual on June 10, 2025 (ACCESSWIRE)
May-20-25 07:00AM	Presenting on Emerging Growth Conference 82 Day 1 on May 21; Register to live stream (GlobeNewswire)
May-07-25 09:15AM	Clene Inc. (CLNN) Reports Q1 Loss, Lags Revenue Estimates (Zacks) -10.53%
08:00AM	Clene Reports First Quarter 2025 Financial Results and Recent Operating Highlights (GlobeNewswire)
08:00AM	Clene Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference (Newsfile)
May-05-25 05:45PM	Certara, Inc. (CERT) Q1 Earnings and Revenues Beat Estimates (Zacks)
Apr-16-25 07:00AM	Presenting on Emerging Growth Conference 81 Day 2 on April 17; Register to live stream (GlobeNewswire)
Apr-15-25 07:00AM	Presenting on Emerging Growth Conference 81 Day 1 on April 16; Register to live stream (GlobeNewswire)
Apr-14-25 08:30AM	Clene to Present at the Emerging Growth Conference (GlobeNewswire)
Apr-08-25 08:00AM	Clene Presents Evidence of Remyelination and Neuronal Repair With CNM-Au8 Treatment At the American Academy of Neurology Late-Breaking Science Session (GlobeNewswire) +7.52%
Apr-01-25 08:30AM	Clene to Present at the Jones Healthcare and Technology Innovation Conference (GlobeNewswire) -16.23%
Mar-25-25 08:30AM	Clene to Participate in Jones Las Vegas Technology and Innovation Conference on April 8-9, 2025 (NewMediaWire) -11.73%
Mar-24-25 09:10AM	Clene Inc. (CLNN) Reports Q4 Loss, Lags Revenue Estimates (Zacks) -5.31%
08:00AM	Clene Reports Full Year 2024 Financial Results and Recent Operating Highlights (GlobeNewswire)
Mar-18-25 03:30PM	Q1 Virtual Investor Summit: On-Demand Presentations Now Live (ACCESS Newswire)
Mar-12-25 08:00AM	Clene Demonstrates Strengthened ALS Survival Benefit with CNM-Au8 Treatment (GlobeNewswire)
Mar-06-25 08:30AM	Clene to Present at the 37TH Annual Roth Conference (GlobeNewswire)
Feb-27-25 09:15AM	Clene Inc. Rob Etherington, CEO, and Morgan Brown, CFO, to Present at the Investor Summit Virtual on March 11 (ACCESSWIRE)
Feb-25-25 08:00AM	Clene and APST Enter Into an Agreement to Support FDA's Recommendation for Long-Term NfL Biomarker Analyses of CNM-Au8 's Impact on NfL Reduction (GlobeNewswire)
Feb-14-25 11:29AM	Is Clene Inc. (CLNN) the Best Nanotech Penny Stock to Invest In? (Insider Monkey) +5.48%
Jan-13-25 11:18AM	IBN Coverage: Clene (NASDAQ: CLNN) Paves Cash Runway to Advance CNM-Au8(R) for ALS (NewMediaWire)
Dec-30-24 09:20AM	IBN Coverage: Clene (NASDAQ: CLNN) Receives FDA Roadmap on Potential Accelerated Pathway for CNM-Au8(R) (NewMediaWire)
Dec-19-24 02:44PM	IBN Coverage: Clene (NASDAQ: CLNN) Secures $10M Debt Facility to Advance Neurodegenerative Disease Treatments (NewMediaWire)
08:00AM	Clene Improves Cash Position and Runway by Securing New Debt Facility to Pay Off Existing Senior Loan (GlobeNewswire)
Dec-11-24 11:15AM	IBN Coverage: Clene (NASDAQ: CLNN) Advances CNM-Au8 in ALS With FDA Guidance on Accelerated Approval Pathway (NewMediaWire)
Dec-10-24 08:30AM	FDA Provides Roadmap for Accelerated Approval Pathway Through Submission of Additional CNM-Au8 Biomarker Data in ALS (GlobeNewswire)
Nov-15-24 07:11AM	Clene price target lowered to $83 from $86 at Canaccord (TipRanks)
Nov-13-24 08:00AM	Clene Reports Third Quarter 2024 Financial Results and Recent Operating Highlights (GlobeNewswire) -9.06%
Oct-25-24 12:09PM	IBN Coverage: Clene (NASDAQ: CLNN) Set to Discuss Lead Candidate Biomarker With FDA Leadership (NewMediaWire)
Oct-21-24 01:13PM	IBN Coverage: Clene (NASDAQ: CLNN) Presents Lead Candidate CNM-Au8(R) Updates at Investor Conferences (NewMediaWire)
Oct-11-24 02:55PM	IBN Coverage: Clene (NASDAQ: CLNN) Closes $7.3M Registered Direct Offering and Concurrent Private Placements (NewMediaWire)
Oct-09-24 01:31PM	IBN Coverage: Clene (NASDAQ: CLNN) Announces Participation at Two Upcoming Investor Conferences (NewMediaWire) +14.04%
08:00AM	Clene to Present at Upcoming October Conferences (GlobeNewswire)
Oct-03-24 10:46AM	IBN Coverage: Clene (NASDAQ: CLNN) Closes on Direct Offering, Concurrent Private Placements Totaling $7.3M (NewMediaWire)
Oct-02-24 07:21AM	IBN Coverage: Clene (NASDAQ: CLNN) Announces Series of Direct Offerings, Concurrent Private Placements (NewMediaWire) +6.30%
Oct-01-24 04:00PM	Clene Announces Closing of $7.3 Million Registered Direct Offering and Concurrent Private Placements and Amendment of Debt Facility (GlobeNewswire)
Sep-30-24 08:30AM	Clene Announces $7.3 Million Registered Direct Offering and Concurrent Private Placements Priced at Market Under Nasdaq Rules (GlobeNewswire)
Sep-26-24 11:44AM	IBN Coverage: Clene (NASDAQ: CLNN) to Discuss CNM-Au8(R) Data FDA Leadership (NewMediaWire)
Sep-16-24 08:30AM	Clene Granted In-Person Meeting With FDA Senior Leadership to Discuss CNM-Au8 Biomarker and Related Clinical and Survival Data (GlobeNewswire) -17.06%
Sep-04-24 11:27AM	IBN Coverage: Clene (NASDAQ: CLNN) Management to Present at H.C. Wainwright Investment Conference (NewMediaWire) +12.50%
Sep-03-24 10:38AM	IBN Coverage: Clene (NASDAQ: CLNN) Positioned as Leader in Addressing Neurodegenerative Diseases (NewMediaWire) +12.33%
08:00AM	Clene to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
Aug-29-24 12:13PM	IBN Coverage: Clene (NASDAQ: CLNN) CEO Discusses CNM-Au8(R) Trial Results on BioMedWire Podcast (NewMediaWire)
Aug-23-24 10:17AM	IBN Coverage: Clene's (NASDAQ: CLNN) CNM-Au8(R) Affects Key Biomarkers, Long-term Survival in ALS Trials (NewMediaWire)
Aug-13-24 12:47PM	IBN Coverage: Clene (NASDAQ: CLNN) Makes Strides in Developing CNM-Au8(R) to Address Neurodegenerative Conditions (NewMediaWire)
Aug-12-24 08:00AM	IBN Coverage: Clene (NASDAQ: CLNN) CEO Spotlighted in Recent BioMedWire Podcast Episode (NewMediaWire)
Aug-09-24 09:00AM	IBN Coverage: Clene (NASDAQ: CLNN) Releases Q2 2024 Financial Results, Provides Updates (NewMediaWire) +14.74%
Aug-08-24 08:00AM	IBN Announces Latest Episode of The BioMedWire Podcast featuring Rob Etherington, CEO of Clene Inc. (GlobeNewswire)
Aug-07-24 08:23AM	Clene Reports Second Quarter 2024 Financial Results and Recent Operating Highlights (GlobeNewswire) -23.47%
Aug-06-24 08:00AM	Clene Announces New CNM-Au8 Biomarker and Clinical Efficacy Data Submitted to FDA In Support of Treatment For ALS (GlobeNewswire) +47.00%
Aug-05-24 08:00AM	Clene to Present at the Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase (GlobeNewswire) -7.62%
Jul-17-24 07:00AM	Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now (GlobeNewswire)
Jul-16-24 07:00AM	Presenting on the Emerging Growth Conference 73 Day 1 on July 17 Register Now (GlobeNewswire)
Jul-12-24 10:34AM	Clene to Present at the Emerging Growth Conference (GlobeNewswire)
Jul-11-24 09:00AM	Clene Announces Plans to Submit Briefing Book to the U.S. Food and Drug Administration in Connection with Granted Type C Interaction to Obtain FDA Feedback on Potential Pathway to Accelerated Approval for CNM-Au8 in ALS (GlobeNewswire) -9.61%
Jul-09-24 08:00AM	Clene Announces 1-for-20 Reverse Stock Split (GlobeNewswire) -21.54%
Jun-24-24 08:00AM	Clene to Present at H.C. Wainwright's 5th Annual Neuro Perspectives Virtual Conference (GlobeNewswire)

Clene, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology therapeutics. It offers a nanotechnology drug platform for the development of a new class of orally administered neurotherapeutic drugs. The company was founded in 2013 and is headquartered in Salt Lake City, UT.

MBARobert Dee Etherington

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Ugwumba Chidozie	10% Owner	May 12 '26	Sale	6.20	73,296	454,435	103,417	May 13 06:04 PM
Ugwumba Chidozie	10% Owner	May 11 '26	Sale	6.75	22,177	149,695	176,713	May 13 06:04 PM
Symbiosis II LLC	Former Board Member	May 11 '26	Proposed Sale	6.50	198,890	1,292,785		May 11 04:15 PM
Ugwumba Chidozie	10% Owner	May 04 '26	Sale	6.80	72,884	495,611	198,890	May 05 05:53 PM
Ugwumba Chidozie	10% Owner	May 01 '26	Sale	6.01	5,795	34,828	271,774	May 05 05:53 PM
Symbiosis II LLC	Former Board Member	May 04 '26	Proposed Sale	6.55	41,260	270,381		May 04 04:02 PM
Ugwumba Chidozie	10% Owner	Apr 29 '26	Sale	5.63	12,170	68,517	283,305	Apr 30 05:54 PM
Ugwumba Chidozie	10% Owner	Apr 30 '26	Sale	6.08	5,736	34,875	277,569	Apr 30 05:54 PM
Ugwumba Chidozie	10% Owner	Apr 28 '26	Sale	5.90	1,591	9,387	295,475	Apr 30 05:54 PM
Symbiosis II LLC	Former Board Member	Apr 28 '26	Proposed Sale	5.90	56,916	335,804		Apr 28 04:10 PM
Ugwumba Chidozie	10% Owner	Apr 21 '26	Sale	6.14	61,345	376,658	297,066	Apr 22 05:55 PM
Ugwumba Chidozie	10% Owner	Apr 20 '26	Sale	6.12	4,318	26,426	358,411	Apr 22 05:55 PM
Ugwumba Chidozie	10% Owner	Apr 17 '26	Sale	6.43	25,040	161,007	362,729	Apr 17 08:17 PM
Ugwumba Chidozie	10% Owner	Apr 16 '26	Sale	6.40	7,748	49,587	387,769	Apr 17 08:17 PM
Ugwumba Chidozie	10% Owner	Apr 15 '26	Sale	6.48	6,374	41,304	395,517	Apr 17 08:17 PM
Symbiosis II LLC	Former Board Member	Apr 15 '26	Proposed Sale	6.39	104,825	669,832		Apr 15 04:05 PM
Ugwumba Chidozie	10% Owner	Apr 02 '26	Sale	4.81	24,925	119,889	401,891	Apr 06 05:32 PM
Ugwumba Chidozie	10% Owner	Apr 01 '26	Sale	4.97	4,278	21,262	426,816	Apr 01 05:10 PM
Symbiosis II LLC	Former Board Member	Mar 24 '26	Proposed Sale	4.89	30,518	149,233		Mar 31 05:05 PM
Ugwumba Chidozie	10% Owner	Mar 31 '26	Sale	4.88	67,991	331,796	431,094	Mar 31 04:35 PM
Ugwumba Chidozie	10% Owner	Mar 27 '26	Sale	4.75	17,470	82,982	514,621	Mar 31 04:35 PM
Ugwumba Chidozie	10% Owner	Mar 30 '26	Sale	5.10	15,536	79,234	499,085	Mar 31 04:35 PM
Ugwumba Chidozie	10% Owner	Mar 25 '26	Sale	5.50	7,098	39,039	537,410	Mar 26 05:39 PM
Ugwumba Chidozie	10% Owner	Mar 24 '26	Sale	5.78	5,492	31,744	544,508	Mar 26 05:39 PM
Ugwumba Chidozie	10% Owner	Mar 26 '26	Sale	5.40	5,319	28,723	532,091	Mar 26 05:39 PM
Symbiosis II LLC	Former Board Member	Mar 24 '26	Proposed Sale	5.80	82,212	477,000		Mar 24 04:36 PM
Ugwumba Chidozie	10% Owner	Feb 03 '26	Sale	4.10	5,559	22,792	550,000	Feb 05 10:18 AM
Symbiosis II LLC	Prior board member	Jan 29 '26	Proposed Sale	4.37	60,842	265,731		Feb 03 03:36 PM
Ugwumba Chidozie	10% Owner	Jan 29 '26	Sale	4.32	15,284	66,027	565,045	Feb 02 05:10 PM
Ugwumba Chidozie	10% Owner	Jan 30 '26	Sale	4.13	5,686	23,483	559,359	Feb 02 05:10 PM
Ugwumba Chidozie	10% Owner	Feb 02 '26	Sale	4.04	3,800	15,352	555,559	Feb 02 05:10 PM
Ugwumba Chidozie	10% Owner	Jan 28 '26	Sale	4.91	8,717	42,800	580,329	Jan 28 05:01 PM
Ugwumba Chidozie	10% Owner	Jan 26 '26	Sale	5.02	6,418	32,218	593,185	Jan 28 05:01 PM
Ugwumba Chidozie	10% Owner	Jan 27 '26	Sale	5.08	4,139	21,026	589,046	Jan 28 05:01 PM
Ugwumba Chidozie	10% Owner	Jan 22 '26	Sale	5.32	12,665	67,378	605,159	Jan 23 05:33 PM
Ugwumba Chidozie	10% Owner	Jan 23 '26	Sale	5.27	5,556	29,280	599,603	Jan 23 05:33 PM
Ugwumba Chidozie	10% Owner	Jan 21 '26	Sale	5.05	12,119	61,201	617,824	Jan 21 06:13 PM
Ugwumba Chidozie	10% Owner	Jan 20 '26	Sale	4.80	12,432	59,674	629,943	Jan 21 06:13 PM
Ugwumba Chidozie	10% Owner	Jan 16 '26	Sale	5.13	7,923	40,645	642,375	Jan 21 06:13 PM
Ugwumba Chidozie	10% Owner	Jan 13 '26	Sale	4.89	26,105	127,653	682,482	Jan 16 11:16 AM
Ugwumba Chidozie	10% Owner	Jan 14 '26	Sale	5.12	19,621	100,460	662,861	Jan 16 11:16 AM
Ugwumba Chidozie	10% Owner	Jan 15 '26	Sale	5.10	12,563	64,071	650,298	Jan 16 11:16 AM
MATLIN DAVID J	Director	Jan 13 '26	Buy	6.50	33,333	216,664	477,824	Jan 13 02:48 PM
Ugwumba Chidozie	10% Owner	Jan 12 '26	Sale	5.50	32,705	179,878	708,587	Jan 12 04:38 PM
Ugwumba Chidozie	10% Owner	Jan 09 '26	Sale	6.27	9,075	56,900	741,292	Jan 12 04:38 PM
Ugwumba Chidozie	10% Owner	Jan 08 '26	Sale	6.09	3,195	19,458	750,367	Jan 12 04:38 PM
Ugwumba Chidozie	10% Owner	Jan 05 '26	Sale	5.87	5,869	34,451	760,611	Jan 07 05:28 PM
Ugwumba Chidozie	10% Owner	Jan 07 '26	Sale	6.29	3,938	24,770	753,562	Jan 07 05:28 PM
Ugwumba Chidozie	10% Owner	Jan 06 '26	Sale	6.04	3,111	18,790	757,500	Jan 07 05:28 PM
Ugwumba Chidozie	10% Owner	Dec 31 '25	Sale	5.81	13,095	76,082	770,495	Jan 02 05:25 PM
Ugwumba Chidozie	10% Owner	Jan 02 '26	Sale	5.73	4,015	23,006	766,480	Jan 02 05:25 PM
Ugwumba Chidozie	10% Owner	Dec 29 '25	Sale	5.95	8,096	48,171	787,728	Dec 31 12:10 PM
Ugwumba Chidozie	10% Owner	Dec 30 '25	Sale	6.03	4,138	24,952	783,590	Dec 31 12:10 PM
Ugwumba Chidozie	10% Owner	Dec 23 '25	Sale	6.27	6,831	42,830	800,664	Dec 30 09:03 PM
Ugwumba Chidozie	10% Owner	Dec 26 '25	Sale	6.32	3,350	21,172	795,824	Dec 30 09:03 PM
Ugwumba Chidozie	10% Owner	Dec 24 '25	Sale	6.27	1,490	9,342	799,174	Dec 30 09:03 PM
Ugwumba Chidozie	10% Owner	Dec 19 '25	Sale	6.45	5,582	36,004	387,568	Dec 23 04:37 PM
Ugwumba Chidozie	10% Owner	Dec 22 '25	Sale	6.54	4,367	28,560	383,201	Dec 23 04:37 PM
Ugwumba Chidozie	10% Owner	Dec 04 '25	Sale	6.73	72,748	489,594	521,620	Dec 18 05:08 PM
Ugwumba Chidozie	10% Owner	Dec 03 '25	Sale	7.86	56,577	444,695	594,368	Dec 18 05:08 PM
Ugwumba Chidozie	10% Owner	Dec 05 '25	Sale	5.94	37,235	221,176	484,385	Dec 18 05:08 PM
Ugwumba Chidozie	10% Owner	Dec 08 '25	Sale	5.70	21,463	122,339	462,922	Dec 18 05:08 PM
Ugwumba Chidozie	10% Owner	Dec 09 '25	Sale	5.95	15,031	89,434	447,891	Dec 18 05:08 PM
Ugwumba Chidozie	10% Owner	Dec 11 '25	Sale	6.81	10,907	74,277	427,063	Dec 18 05:08 PM
Ugwumba Chidozie	10% Owner	Dec 15 '25	Sale	6.49	10,580	68,664	408,880	Dec 18 05:08 PM
Ugwumba Chidozie	10% Owner	Dec 10 '25	Sale	6.42	9,921	63,693	437,970	Dec 18 05:08 PM
Ugwumba Chidozie	10% Owner	Dec 12 '25	Sale	6.79	7,603	51,624	419,460	Dec 18 05:08 PM
Ugwumba Chidozie	10% Owner	Dec 16 '25	Sale	6.31	7,030	44,359	401,850	Dec 18 05:08 PM
Ugwumba Chidozie	10% Owner	Dec 18 '25	Sale	6.33	5,816	36,815	393,150	Dec 18 05:08 PM
Ugwumba Chidozie	10% Owner	Dec 17 '25	Sale	6.61	2,884	19,063	398,966	Dec 18 05:08 PM
Symbiosis II LLC	Prior Board Member	Dec 03 '25	Proposed Sale	7.46	506,384	3,775,481		Dec 05 04:14 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CLNN

Clene Inc

Upgrade your Finviz experience